$276 Million is the total value of Ghost Tree Capital, LLC's 40 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 150.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR SERIES TRUSTcall | $53,813,000 | – | 750,000 | +100.0% | 19.53% | – |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $13,363,000 | -20.4% | 1,250,000 | +13.6% | 4.85% | +35.9% |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $13,257,000 | – | 80,000 | +100.0% | 4.81% | – |
| IMMU | New | IMMUNOMEDICS INCput | $11,416,000 | – | 800,000 | +100.0% | 4.14% | – |
| RTRX | Buy | RETROPHIN INC | $11,315,000 | +12.5% | 500,000 | +42.9% | 4.11% | +92.1% |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO L | $10,170,000 | +35.4% | 275,000 | +37.5% | 3.69% | +131.3% |
| ANAB | Buy | ANAPTYSBIO INC | $8,931,000 | +49.2% | 140,000 | +133.3% | 3.24% | +154.8% |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $8,892,000 | -9.7% | 600,000 | +50.0% | 3.23% | +54.2% |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $8,850,000 | – | 1,000,000 | +100.0% | 3.21% | – |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $8,394,000 | +68.7% | 425,000 | +88.9% | 3.05% | +188.2% |
| OBSV | Buy | OBSEVA SA | $6,963,000 | -27.8% | 550,000 | +2.8% | 2.53% | +23.3% |
| BOLD | New | AUDENTES THERAPEUTICS INC | $6,396,000 | – | 300,000 | +100.0% | 2.32% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $6,227,000 | – | 650,000 | +100.0% | 2.26% | – |
| ORTX | New | ORCHARD THERAPEUTICS PLCads | $4,719,000 | – | 300,000 | +100.0% | 1.71% | – |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $4,105,000 | +800.2% | 100,000 | +733.3% | 1.49% | +1436.1% |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $3,588,000 | – | 325,000 | +100.0% | 1.30% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INput | $3,489,000 | – | 85,000 | +100.0% | 1.27% | – |
| SAGE | New | SAGE THERAPEUTICS INCcall | $2,874,000 | – | 30,000 | +100.0% | 1.04% | – |
| ITCI | New | INTRA CELLULAR THERAPIES INCcall | $904,000 | – | 79,400 | +100.0% | 0.33% | – |
| PTI | New | PROTEOSTASIS THERAPEUTICS IN | $616,000 | – | 190,000 | +100.0% | 0.22% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-04-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| ASCENDIS PHARMA A/S - ADR | 28 | Q3 2023 | 11.8% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2023 | 9.1% |
| SPDR SER TR | 20 | Q3 2022 | 16.9% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SAGE THERAPEUTICS INC | 18 | Q1 2021 | 4.8% |
| IMMUNOMEDICS INC | 17 | Q2 2020 | 8.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-16 |
| 13F-HR | 2021-11-15 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.